News
-
-
-
PRESS RELEASE
OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
OSE Immunotherapeutics launches international Phase 3 trial 'Artemia' of cancer vaccine Tedopi® in second-line NSCLC treatment, aiming for regulatory approval in Europe and North America -
PRESS RELEASE
OSE Immunotherapeutics annonce le lancement international d’Artemia, l’étude de Phase 3 d’enregistrement du vaccin thérapeutique Tedopi® en deuxième ligne de traitement du cancer du poumon non à petites cellules
OSE Immunotherapeutics lance l'étude internationale d'Artemia en Phase 3 pour Tedopi® contre le cancer du poumon non à petites cellules, aux États-Unis, Canada, Europe, Royaume-Uni, avec présentations aux conférences WCLC et ESMO -
-
-
-
PRESS RELEASE
SpexPro: Mister Spex Launches Private Label for Premium Eyewear Lenses
Mister Spex SE launches premium eyewear lenses under the private label 'SpexPro', aiming to enhance visual comfort, protection, and durability in prescription eyewear. The introduction of SpexPro lenses supports the company's growth strategy and profitability targets -
PRESS RELEASE
Bellevue expands its Sales team for the Swiss market
Bellevue Asset Management AG announces the recruitment of Livia Zanini as Senior Sales Switzerland, enhancing the Sales team for the Swiss market. Livia brings extensive experience in financial advisory services and diverse product knowledge -
PRESS RELEASE
ENCAVIS successfully closed a project financing in the amount of approx. EUR 61 million for its German solar park in Borrentin (114 megawatts)
Encavis AG closed EUR 61 million project financing for German solar park in Borrentin. Financing supported by Bayerische Landesbank for future growth strategy
